Showing 721-730 of 1367 results for "".
- IgE Identified as Key Mediator in Psoriasis and Atherosclerosis Comorbidityhttps://practicaldermatology.com/news/ige-identified-as-key-mediator-in-psoriasis-and-atherosclerosis-comorbidity/2471009/A new review points to immunoglobulin E (IgE) as a potential central player in the overlapping mechanisms of psoriasis and atherosclerosis. Researchers writing in Biomedicine and Pharmacotherapy proposed IgE-mediated mast cell (MC) activation as a significant contributor to the progressio
- GHG Audit Shows Key Emission Sources in Dermatology Practicehttps://practicaldermatology.com/news/ghg-audit-shows-key-emission-sources-dermatology-practice/2470894/A new study has identified scope 3 emissions, particularly purchased goods and services, as the largest contributor to the carbon footprint of an outpatient dermatology clinic, accounting for 51.1% of total greenhouse gas (GHG) emissions. The research, conducted at a University of Pennsylv
- Key Thickness Benchmark Identified for Thin Melanoma Death Riskhttps://practicaldermatology.com/news/key-thickness-benchmark-identified-thin-melanoma-death-risk/2470668/Melanomas with Breslow thickness between 0.8 and 1.0 mm are associated with nearly triple the risk of melanoma-related death compared to thinner melanomas, a new study of Australian registry data reports. "Most patients who present with primary cutaneous melanomas have thin tumors (≤ 1.0 m
- Study: TPC2 Ion Channel Key Driver of Melanoma Progressionhttps://practicaldermatology.com/news/study-tpc2-ion-channel-key-driver-melanoma-progression/2468665/New research has succeeded in identifying a critical regulator of melanoma progression. The research, published by a group from Ludwig-Maximilians-Universität München in Nature Communications, highlights how TPC2 influences intracellular trafficking pathways that drive melanoma c
- Panel Agrees on Key Recommendations for Oral Minoxidil Usehttps://practicaldermatology.com/news/panel-agrees-key-recommendations-oral-minoxidil-use/2468659/A new international consensus statement offers guidance on the off-label use of low-dose oral minoxidil (LDOM) for managing hair loss. The
- Study Identifies Key Patient-Centered Attributes of Atopic Dermatitis Flarehttps://practicaldermatology.com/news/study-identifies-key-patient-centered-attributes-ad-flare/2468156/A new study revealed a consensus on the patient-centered definition of an atopic dermatitis (AD) flare. Researchers for the study recruited 26 participants for focus groups and 631 participants for a survey through the National Eczema Association. The participants rated various attributes
- Panel IDs Key Skincare Strategies for Adult Acnehttps://practicaldermatology.com/news/dermatologists-identify-key-skincare-strategies-adult-acne/2467834/New research featuring input from an expert acne panel emphasized the critical importance of skin care in managing adult acne. The panel, consisting of eight dermatologists, looked at the role of skin barrier function in adult acne and the benefits of adjunctive skin care, such as cleanse
- Nemolizumab Meets Key Endpoints in ARCADIA Studieshttps://practicaldermatology.com/news/nemolizumab-meets-key-endpoints-arcadia-studies/2467533/Nemolizumab, a monoclonal antibody targeting the IL-31 receptor, showed efficacy for the treatment of atopic dermatitis, particularly pruritus and sleep disturbance, according to an announcement from Galderma. The full results of the phase III ARCADIA 1 and 2 trials for nemolizumab were pu
- FDA Takes Key Step on Tapinarof for ADhttps://practicaldermatology.com/news/fda-takes-key-step-tapinarof-ad/2467002/The US Food and Drug Administration has accepted a supplemental new drug application for Dermavant’s VTAMA (tapinarof) following positive results of a Phase III clinical trial for the drug’s use on atopic dermatitis patients 2 and older, according to GlobalData. Tapinarof, an aryl hydrocar
- Is Separating the Good Skin T Cells from the Bad Ones a Key to Treating Psoriasis and Vitiligo?https://practicaldermatology.com/news/is-separating-the-good-skin-t-cells-from-the-bad-ones-a-key-to-treating-psoriasis-and-vitiligo/2462162/New research highlights ways to remove immune cells that cause autoimmune skin diseases such as psoriasis and vitiligo without affecting protective cells that fight infection and cancer. Tissue-resident T cells or TRM cells fight infections and cancerous cells in the skin, but